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Objectives
To investigate risk of AIDS and mortality after transition from paediatric to adult care in a UK
cohort of young people with perinatally acquired HIV.
Methods
Records of people aged ≥ 13 years on 31 December 2015 in the UK paediatric HIV cohort
(Collaborative HIV Paediatric Study) were linked to those of adults in the UK Collaborative HIV
Cohort (CHIC) cohort. We calculated time from transition to a new AIDS event/death, with follow-
up censored at the last visit or 31 December 2015, whichever was the earliest. Cumulative
incidence of and risk factors for AIDS/mortality were assessed using Kaplan–Meier and Cox
regression.
Results
At the final paediatric visit, the 474 participants [51% female, 80% black, 60% born outside the
UK, median (interquartile range) age at antiretroviral therapy (ART) initiation = 9 (5–13) years] had
a median age of 18 (17–19) years and CD4 count of 471 (280–663) cell/lL; 89% were prescribed
ART and 60% overall had a viral load ≤ 400 copies/mL. Over median follow-up in adult care of 3
(2–6) years, 35 (8%) experienced a new AIDS event (n = 25) or death (n = 14) (incidence = 1.8/100
person-years). In multivariable analyses, lower CD4 count at the last paediatric visit [adjusted
hazard ratio = 0.8 (95% confidence interval: 0.7–1.0)/100 cells/lL increment] and AIDS diagnosis
in paediatric care [2.7 (1.4–5.5)] were associated with a new AIDS event/mortality in adult care.
Conclusions
Young people with perinatally acquired HIV transitioning to adult care with markers of disease
progression in paediatric care experienced poorer outcomes in adult care. Increased investment in
multidisciplinary specialized services is required to support this population at high risk of
morbidity and mortality.
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Introduction
With advancements in antiretroviral therapy (ART) and
subsequent declines in morbidity and mortality, the life
expectancy of adults living with HIV in many settings is
nearing that of the general population [1,2]. Similar
declines in AIDS events, hospitalizations and mortality in
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children living with perinatally acquired HIV (PHIV) have
also been reported, in particular from high-income set-
tings [3–5]. However, less is known about the impact of
lifelong exposure to HIV and ART on mortality as this
group reaches adolescence and adulthood, and transitions
to adult care [6].
In 2015, mortality associated with HIV was the eighth
leading cause of adolescent deaths globally [7], but in
many settings, following children as they move through
paediatric care and transition to adult care is challenging
for several reasons, including disjointed health systems
and lack of capacity to conduct longitudinal research. Of
the studies that have measured mortality in adult care [8–
12], some are smaller cohorts that may not be representa-
tive of the wider population of young people living with
PHIV in their respective setting. The UK benefits from a
national paediatric cohort, which includes all children
diagnosed with HIV and in paediatric care, embedded
within the National Health Service, and an ongoing large
observational cohort of adults receiving care for HIV
[13,14], We conducted data linkage of these two cohorts,
which enabled us to assess the incidence of AIDS events
and mortality, as well as identify any risk factors, among
young people with HIV who transitioned from paediatric
to adult care across clinical settings in the UK.
Methods
Study design and participants
In the UK, all children born to women with HIV, and those
diagnosed with HIV aged < 16 years are reported to the
National Surveillance of HIV in Pregnancy and Childhood
(NSHPC). They are subsequently followed through paedi-
atric care in the Collaborative HIV Paediatric Study
(CHIPS), although follow-up ceases when they transfer to
adult care [13,15], The UK Collaborative HIV Cohort (CHIC)
Study is an ongoing study collecting clinical data of adults
aged ≥ 16 years accessing HIV care from some of the lar-
gest HIV clinics in the UK [14], and thus includes any
young people followed in CHIPS who have transferred to
one of the 25 participating adult clinics. Deaths are
reported to the UK CHIC Study by participating clinics and
additional mortality reports are obtained through annual
linkage to national surveillance reports coordinated by
Public Health England (PHE). Both CHIPS and the UK CHIC
Study have NHS research ethics approval.
Statistical methods
Records of young people aged ≥ 13 years by 31 Decem-
ber 2015 who had received paediatric care in the UK and
been followed in CHIPS were linked to their respective
adult care records in UK CHIC (with data available to 31
December 2015) using deterministic data linkage. A mul-
ti-step linkage process was used which included combina-
tions of the following variables: date of birth, sex,
Soundex (a non-unique code derived from patient’s sur-
name [16]), clinic identifier, clinic name and initials. Val-
idation of linked records was conducted using additional
demographic and clinical variables. As only participants
with linked records and one or more completed adult care
visit at a UK CHIC clinic were included in subsequent
analyses, characteristics of this group were compared
with young people who had transferred to adult care but
who were not identified in the UK CHIC linkage, to assess
representativeness. Proportions were compared using the
v2 test, and medians using the Mann–Whitney test.
We used a composite endpoint of a new clinical AIDS
event or death occurring after the date of the last paediatric
visit, rather than a single endpoint of death, due to the reas-
suringly small number of deaths observed. Demographic
and clinical characteristics at the last paediatric visit were
compared between those with and without the composite
endpoint, and causes of death, clinical and ART status at
time of death were also described. Time at risk was calcu-
lated from the date of the last paediatric care visit to the date
of the first new AIDS event or death, with follow-up being
right-censored on the last date of adult follow-up or the
administrative censoring date of 31 December 2015 (which-
ever was earliest) for those who did not experience one of
these events. The cumulative incidence per 100 person-years
of a new AIDS event or death in adult care was assessed
using the Kaplan–Meier estimator.
Factors associated with a new AIDS event or death
were identified using Cox regression. Sex, age at HIV
diagnosis in the UK, and calendar year of the last paedi-
atric care visit were included as a priori factors in all
models, regardless of statistical significance. Age at ART
start and calendar year at ART start were not included in
the models due to their high correlation and issues of
collinearity with age at HIV diagnosis; the variables
included were considered more influential on outcomes
post-transition. Other potential risk factors were identified
using a stepwise backwards elimination approach with an
exit probability of 0.05. Sociodemographic factors con-
sidered were ethnicity (black vs. white/other) and country
of birth (UK vs. abroad). Additionally, the following indi-
cators of clinical status at last paediatric care visit were
considered: nadir CD4 and CD4 count, viral load > 400
copies/mL in the previous year, AIDS diagnosis in paedi-
atric care, ART status, and the duration between the last
paediatric and first adult visit. All analyses were carried
out in STATA v.14 (StataCorp, College Station, TX, USA).
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Results
Of 1683 eligible young people in CHIPS, 546 (32%) were
linked to records in the UK CHIC Study, of whom 474
were confirmed in CHIPS as having transferred to adult
care. Among the remaining 1137 young people with
records not linked to the UK CHIC dataset, 479 were doc-
umented in CHIPS to have transferred to adult care. Char-
acteristics of both groups are presented in Table 1. Of
those with records that were linked to the UK CHIC
Study, the vast majority (96.2%) had perinatally acquired
HIV, half (50.8%) were female, four-fifths (80.2%) were
black and two-thirds (60.4%) were born outside of the
UK. Median (interquartile range, IQR) calendar year of
birth was 1993 (1990–1995), and median age at HIV
diagnosis in the UK was 6.0 (2.2–10.7) years. Almost 92%
of children started ART in paediatric care, and median
age at ART start was 8.8 (4.8–12.5) years.
At the last paediatric care visit, the median age was
17.7 (16.7–18.5) years, and median calendar year was
2011 (2008–2013). Median CD4 count was 471 (280–663)
cells/lL, and 59.9% overall (66% on ART) had viral
load ≤ 400 copies/mL. At the last paediatric visit, a quar-
ter (27.6%) had a prior AIDS event in paediatric care, for
which the median (IQR) age at first AIDS event was 6.9
(2.6–11.5) years. Additionally, at this last paediatric visit
89.0% were prescribed ART, and of the 11% who were
not on ART, 76% (39/51) were ART-na€ıve. Median (IQR)
duration of follow-up in paediatric care was 12 (7–16)
years, and young people had a median gap in care
between their last paediatric visit and first adult visit of 3
(2–6) months.
Young people with records linked to the UK CHIC
Study were largely similar to young people without
linked records; the key differences were that those with
linked records were born in earlier calendar years and
had their last paediatric clinic visit in earlier calendar
years (both P < 0.001), and the median CD4 count and
proportion virally suppressed at last paediatric visit were
lower (P < 0.001 and P = 0.007, respectively).
Of the 474 young people linked to UK CHIC, 14 were
excluded as they had no subsequent visits after the first
adult visit, so their time at risk could not be estimated. Of
the remaining 460, 25 experienced a new AIDS event and
14 died in adult care, with 35 meeting the composite
endpoint of AIDS or mortality, during a median (IQR) fol-
low-up in adult care of 3 (2–6) years. The AIDS events in
adult care included candidiasis (n = 7, of which six were
oesophageal and one unknown), herpes simplex infection
(n = 1), Kaposi’s sarcoma (n = 1), Burkitt’s lymphoma
(n = 1), pulmonary/disseminated tuberculosis (n = 5),
Pneumocystis jiroveci pneumonia (n = 2), pneumonia
(n = 1), progressive multifocal leukoencephalopathy
(n = 1), cerebral toxoplasmosis (n = 2), HIV wasting syn-
drome (n = 1) and unspecified (n = 3). Of the 14 who
died, four were diagnosed with a new AIDS event in adult
Table 1 Demographic, antiretroviral therapy (ART) and clinical characteristics at baseline and last paediatric clinic visit by linkage status to
the UK Collaborative HIV Cohort (CHIC)
Total (n = 953) Linked to UK CHIC (n = 474) Not linked to UK CHIC (n = 479)
P valuen (%) or median (interquartile range)
Demographic and ART baseline
Perinatally acquired HIV 870 (95.9) 435 (96.2) 435 (95.6) 0.63
Female sex 503 (52.8) 241 (50.8) 262 (54.7) 0.23
Black ethnicity 738 (77.4) 380 (80.2) 358 (74.7) 0.05
Born abroad 558 (61.5) 281 (60.4) 293 (62.3) 0.52
Calendar year of birth 1994 (1991,1996) 1993 (1990–1995) 1995 (1992–1997) < 0.001
Age at HIV diagnosis (years) 6.6 (2.5–11.0) 6.0 (2.2–10.7) 7.3 (3.0–11.1) 0.05
Started ART in paediatric care 868 (91.1) 434 (91.6) 434 (90.6) 0.61
Combination ART regimen at ART initiation 575 (60.3) 270 (57.0) 305 (63.7) 0.04
Age at ART initiation (years) 8.8 (4.7–12.6) 8.8 (4.8–12.5) 8.9 (4.4–12.8) 0.78
Last paediatric clinic visit
Age (years) 17.7 (16.8–18.5) 17.7 (16.7–18.5) 17.7 (16.9–18.4) 0.99
Calendar year 2012 (2009–2014) 2011 (2008–2013) 2012 (2009–2015) < 0.001
Nadir CD4 count (cells/lL) 204 (98–310) 200 (90–293) 215 (110–326) 0.05
CD4 count (cells/lL) 500 (317–683) 471 (280–663) 528 (360–697) < 0.001
Viral load ≤ 400 copies/mL 603 (64.2) 278 (59.9) 325 (68.4) 0.007
Prior AIDS event (CDC C) 247 (25.9) 131 (27.6) 116 (24.2) 0.01
ART status
Prescribed ART 852 (89.4) 422 (89.0) 430 (89.8) 0.71
ART-na€ıve/ off ART 101 (10.6) 52 (11.0) 49 (10.6)
Duration in paediatric care (years) 11.2 (6.9–15.1) 12.0 (7.4–15.5) 10.4 (6.4–14.8) 0.01
Duration between last paediatric and first
adult visits (months)
Not known 3.2 (1.6–6.2) Not known
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care: one person had their first AIDS diagnosis in adult
care at the time of their death, and for the other three the
first AIDS event was around 1–4 years prior to death.
Causes of death were advanced HIV disease (n = 3), HIV
wasting (n = 1), non-HIV/AIDS-related (n = 1), suicide
(n = 1), renal failure (n = 1), respiratory disease (n = 2),
multifocal leukoencephalopathy (n = 1) and unspecified
(n = 4). Nine of the 14 were female, 79% were born
abroad, age at death was in the range 18–23 years, and
the median (IQR) calendar year of death was 2010 (2009–
2013). Deaths occurred a median of 4 (3–5) years follow-
ing the last paediatric visit. At the last paediatric visit, 12
(86%) of those who died had been prescribed ART, four
(29%) had a viral load ≤ 400 copies/mL and the median
(IQR) CD4 count was 150 (83–383) cells/lL. By the date
of the last adult care visit prior to death (with the date of
last visit being the same as the date of death for 11 of
the 14 who died), 10 of the 14 were being prescribed
ART, and the median (IQR) CD4 count was 35 (15–200)
cells/lL. The viral loads of most of the 14 young people
who died were uncontrolled before, and continued to
increase after, transition, although many had persistently
low CD4 counts, often nearing 0 cells/lL, in adult care
(Fig. 1).
Incidence of AIDS and mortality in adult care and
associated risk factors
Overall, the crude mortality rate was 0.6/100 person-years
[95% confidence interval (CI): 0.4–1.1)] and the rate of new
AIDS events/mortality was 1.8 (1.3–2.5)/100 person-years.
The incidence of new AIDS events/mortality increased
steadily over the first 5 years of adult care (Fig. 2) and rates
were 1% (0–2%), 4% (2–6%) and 9% (6–13%) by 1, 3 and 5
years of adult follow-up, respectively (Fig. 2).
Table 2 presents rates of, and factors potentially asso-
ciated with, new AIDS events /mortality in adult care. In
univariable analyses, rates were lower in those who
transferred to adult care in later calendar years, those
born in the UK, and those with a higher nadir CD4 or
CD4 count at last paediatric visit. In addition, rates were
higher among those with a viral load > 400 copies/mL in
the last year of paediatric care and in those with an AIDS
diagnosis in paediatric care. In the multivariable model, a
priori factors (sex, age at HIV diagnosis, calendar year of
last paediatric visit) were not associated with the out-
come. Of the other potential factors, lower CD4 count at
last paediatric care visit [adjusted hazard ratio (aHR)
(95% CI) = 0.8 (0.7–1.0)/100 cells/lL increase, P = 0.03]
and an AIDS diagnosis in paediatric care [aHR = 2.7 (1.4–
5.5), P = 0.004] remained significant after adjustment for
other factors.
Discussion
Our study, using linked data from the CHIPS and UK CHIC
Study cohorts, is one of the largest multi-centre studies of
young people with perinatal HIV transitioning from paedi-
atric to adult care. We reported a high incidence of new
AIDS events/mortality in adult care for this population.
Choice of this composite endpoint enabled us to investigate
associations with socio-demographic characteristics of
these young people as well as their characteristics at their
last paediatric care visits. We showed that young people at
greatest risk of experiencing a new AIDS event or death
following transfer to adult care were those who had an
AIDS diagnosis in paediatric care, or who had a lower CD4
count at their last paediatric care visit. Our findings high-
light the clinical complexities of this cohort, with nearly 1
in 10 people experiencing an AIDS-defining event or dying
by 5 years’ follow-up in adult care.
Overall, 35 people in our analysis experienced a new
AIDS event or died after transitioning to adult care. The
mortality rate in our study, of 0.6/100 person-years, is
more than 12 times higher than the mortality rate in the
general population of people aged < 25 years in the UK
(0.03–0.05/100 person-years) [17], highlighting the ongo-
ing vulnerability of our cohort despite widespread ART
access. Our rate of adverse outcomes is lower than a study
of 735 young people with PHIV in New York who transi-
tioned to adult care at a median age of 22 years [11]. In
that study, the mortality rate was 5.6/100 person-years in
the first year after transition to adult care, with most deaths
in the first 6 months of adult care. By contrast, most deaths
in our study occurred more than 3 years after the last pae-
diatric care visit. However, there were differences between
the two studies in terms of age at transition to adult care
and healthcare systems. The New York cohort transitioned
at a median age of 22 years, so were older than our cohort
at the time of transition to adult care. Furthermore, the
New York patients who transitioned to adult care had
poorer health status than those who remained in paediatric
care, with paediatric care continuing to be available up to
age 25 years in some settings and populations in the USA
[18]. Our analysis updates a previous mortality study
among young people with PHIV attending 14 clinics in
England, which reported eight deaths in adult care, some
of which may also be included in our findings [10], The
previous study found a mortality rate in adult care of 0.5
and 0.9 for those aged 16–20 years and ≥ 21 years,
respectively, similar to what we report here.
In our study, the two significant predictors of AIDS
and mortality in the multivariable analysis were lower
CD4 count at last paediatric care visit and having had an
AIDS diagnosis in paediatric care (at median age 7 years),
© 2021 The Authors.
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which themselves indicate suboptimal health outcomes in
paediatric care. Lower CD4 count at last paediatric care
visit is an indicator of young people who struggle to
manage their HIV infection, and these young people may
benefit most from more intense interventions prior to and
continuing into adult care. Longer-term follow-up is
Fig. 1 CD4 count, log10(viral load) and age at transfer date and death among the 14 young people who died in adult care. Note that similar
graphs for seven of the 14 patients who died were published in a previous paper [13]
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needed to evaluate mortality trends among adults with
PHIV as they reach older ages. In the previous study in
England [9], it was noted that all young people who died
had potentially suppressive ART regimens available to
them, and many had documented adherence problems in
paediatric care, although in this analysis resistance data
were not available. Other research suggests that HIV may
contribute to neurological changes which themselves may
affect outcomes such as adherence [19]. Additionally, as
brain maturation completes at around 25 years of age, it
may be the case that adherence improves and mortality
starts to decline in young people with PHIV who survive
to their mid-20s, establish regular ART treatment habits
and achieve full viral suppression [20–22].
Our study had several limitations. First, the 21 clinics
that participate in the UK CHIC study include several spe-
cialized, tertiary-care HIV clinics located in London and
the south-east of the UK, potentially limiting the general-
izability of our findings to non-tertiary-care settings and
other UK regions. We tried to address this potential bias
Fig. 1 (Continued)
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by comparing characteristics of young people who had
transitioned to adult care by whether they had been
linked to the UK CHIC Study or not, and CD4 counts and
viral load at transfer were, on average, poorer among
those going to UK CHIC clinics. Consequently, our study
may have some selection bias in favour of young people
with poorer health who may have been more likely to be
referred to tertiary clinics with better adolescent care
provision, which may therefore result in overestimates of
rates of AIDS events and mortality. Our study required
young people to have at least one adult visit, and thus
the design prevented us from measuring mortality in
young people who transitioned to non-UK CHIC clinics,
or those who may have died before they had an adult
care visit, or compare mortality with that immediately
pre-transition. We were also limited to routine clinical
record data in our exploration of risk factors for AIDS
and mortality. However, as suggested by Fish et al. [10],
AIDS and mortality may be driven by a multitude of
other factors, such as mental health and ART adherence.
Additionally, our analysis was limited to factors at last
paediatric care visit which were associated with
AIDS/mortality, while future analyses might take a time-
updated approach to ART, viral load and CD4 measures.
Further, our ART measure may have been subject to mis-
classification if young people being prescribed ART and
therefore categorized as ‘on ART’ in our analysis were, in
reality, not taking it. Lastly, given the small number of
events, our multivariable model may be overfitted (five
covariates in the final model) which could reduce the
accuracy of the exposure estimates. However, the major
strengths of our study were the relatively large sample
size and the multiple clinics included.
Fig. 2 Cumulative incidence of AIDS/mortality in adult care.









ratio (95% CI) P-value
Adjusted hazard
ratio (95% CI) P-value
A priori
Sex
Male 13 925 1.4 (0.8–2.4) 1 1
Female 22 1019 2.2 (1.4–3.3) 1.5 (0.8–3.1) 0.21 1.5 (0.7–3.0) 0.25
Age at HIV diagnosis, per year older – – – 1.0 (1.0–1.1) 0.38 1.0 (1.0–1.1) 0.39
Calendar year of last paediatric visit, per year later – – – 0.9 (0.8–1.0) 0.002 0.9 (0.9–1.0) 0.14
Demographic
Ethnicity
Black 31 1510 2.1 (1.4–2.9) 1
White/other 4 395 1.0 (0.4–2.7) 0.5(0.2–1.4) 0.18
Country of birth
Abroad 27 1142 2.4 (1.6–3.4) 1
UK 8 758 1.1 (0.5–2.1) 0.4 (0.2–1.0) 0.04
Last paediatric care visit
CD4 nadir, per 100 cells/lL increase – – – 0.8 (0.6–1.0) 0.07
CD4 count, per 100 cells/lL increase – – – 0.8 (0.7–0.9) 0.002 0.8 (0.7–1.0) 0.03
Viral load > 400 copies/mL in previous year
No 8 7520 1.1 (0.5–2.2) 1
Yes 27 1137 2.4 (1.6–3.6) 2.2 (1.0–4.8) 0.05
AIDS diagnosis in paediatric care
No 16 1426 1.1 (0.7–1.8) 1 1
Yes 19 519 3.7 (2.3–5.7) 3.3 (1.7–6.5) 0.001 2.7 (1.4–5.5) 0.004
ART status
On ART 30 1658 1.8 (1.3–2.6) 1
ART-na€ıve/off ART 5 287 1.7 (0.7–4.2) 1.1 (0.4–2.8) 0.87
Gap between last paediatric and first
adult visit, per month longer
– – – 1.0 (0.98–1.01) 0.72
ART, antiretroviral therapy; CI, confidence interval.
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In conclusion, our study found that young people with
PHIV who transitioned to adult care with poorer
immunological markers and a history of more advanced
disease progression were at increased risk of AIDS events
and death in adult care. A majority of young people with
perinatal HIV who died experienced consistently poor
immunological and virological control during their paedi-
atric and adult follow-up. It does not appear, therefore, to
be transition per se that results in poorer ART adherence,
but instead a continued pattern of suboptimal adherence
established in early adolescence while in paediatric care.
Investment in appropriate and relevant multidisciplinary
support services in paediatric and adult HIV care is essen-
tial to minimize this population’s high risk of morbidity
and mortality, not to mention the potential for onward
HIV transmission.
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